Marksans Pharma Share Price
Small Cap | Pharmaceuticals and health care | NSE: MARKSANS | BSE: 524404
₹206.69 
-26.46 (-11.35 %)
Last Updated: 04 Apr 2025 03:59 PM
BEARISH
Overview
Open (₹) 233.00
High (₹) 233.50
Low (₹) 202.10
Prev. Close (₹) 233.15
Volume 41,29,430
VWAP (₹) 204.98
ROCE (%) 18.97
Industry P/E 44.73
TTM P/E 25.42
P/B Ratio 4.49
Market Cap (₹) Cr.9,366.44
Dividend Yield (%)0.29
EPS (₹) 6.92
ROE15.03%
Sales Growth (%) 17.56
Profit Growth (%)18.68
Day Range
233.50233.50
52 Week Range
130.15358.50
Historical Returns
Returns (6M)
-24.3 %
Returns (1Y)
28.38 %
Returns (3Y)
256.06 %
Returns (5Y)
1064.45 %
Returns (6M)
-24.3 %
Returns (1Y)
28.38 %
Returns (3Y)
256.06 %
Returns (5Y)
1064.45 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (7.96%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Company with 7.96% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Increasing Revenue every Quarter for the past 4 Quarters
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 34.19
MFI 15.47
ATR 14.84
Commodity Channel Index -162.16
ROC125 -12.54
ROC21 -14.91
Williams %R -95.23
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 211.04 | 217.38 | 222.35 | 206.07 | 199.73 | 194.76 | 188.42 |
| Week Ago | 233.80 | 241.55 | 246.30 | 229.05 | 221.30 | 216.55 | 208.80 |
| Month Ago | 236.39 | 245.17 | 254.69 | 226.87 | 218.09 | 208.57 | 199.79 |
EMA & SMA
206.69
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 220.42
9 Day 228.35
10 Day 226.90
12 Day 234.78
14 Day 238.86
20 Day 241.71
26 Day 241.51
50 Day 263.07
100 Day 282.16
200 Day 243.86
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| UBS PRINCIPAL CAPITAL ASIA LIMITED | bulk | Sell | 20 Sept, 2024 | ₹317.22 | 34,01,630 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | bulk | Sell | 20 Sept, 2024 | ₹305.27 | 24,51,180 | NSE |
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND | bulk | Buy | 20 Sept, 2024 | ₹316.85 | 26,97,280 | NSE |
| VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | bulk | Buy | 20 Sept, 2024 | ₹316.85 | 23,01,640 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | bulk | Buy | 20 Sept, 2024 | ₹305.27 | 24,51,180 | NSE |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | bulk | Buy | 15 Apr, 2024 | ₹158.00 | 66,00,000 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | bulk | Sell | 15 Jun, 2021 | ₹93.09 | 30,04,279 | NSE |
| CRONY VYAPAR PVT LTD | bulk | Sell | 15 Jun, 2021 | ₹93.69 | 28,00,172 | NSE |
| GRAVITON RESEARCH CAPITAL LLP | bulk | Buy | 15 Jun, 2021 | ₹93.18 | 30,04,279 | NSE |
| CRONY VYAPAR PVT LTD | bulk | Buy | 15 Jun, 2021 | ₹93.75 | 29,00,172 | NSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 06 Jun, 2024 | Sandra Saldanha | Acquisition | ₹141.48 | 63,276 | NSE |
| 04 Jun, 2024 | Sandra Saldanha | Acquisition | ₹146.01 | 47,000 | NSE |
| 22 Aug, 2023 | Arvind Singh | Acquisition | ₹115.75 | 3,000 | NSE |
| 22 Aug, 2023 | Arvind Singh | Disposal | ₹163.92 | 2,000 | NSE |
| 22 Aug, 2023 | Arvind Singh | Disposal | ₹114.90 | 3,000 | NSE |
| 22 Aug, 2023 | Arvind Singh | Disposal | ₹117.06 | 6,500 | NSE |
| 16 Mar, 2023 | Sandra Saldanha | Acquisition | ₹66.69 | 1,45,000 | NSE |
| 02 Mar, 2023 | Mark Saldanha | Acquisition | ₹74.00 | 10,00,000 | NSE |
| 01 Mar, 2023 | Sandra Saldanha | Acquisition | ₹67.46 | 75,000 | NSE |
| 02 Mar, 2020 | Mr. Sebastian Pereira | Disposal | ₹108.60 | 5,100 | NSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 30 May, 2024 | Rs.0.6000 per share(60%)Final Dividend | 17 Sept, 2024 | 17 Sept, 2024 |
| 25 May, 2023 | Rs.0.5000 per share(50%)Final Dividend | 07 Jun, 2023 | 07 Jun, 2023 |
| 30 May, 2022 | Rs.0.2500 per share(25%)Final Dividend | 19 Aug, 2022 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 31 Mar, 2025 | NSE India | MARKSANS PHARMA LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent |
| 31 Mar, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange regarding Cessation of Mr. Seetharama Raju Buddharaju, as Independent Director of the company w.e.f. March 31, 2025. |
| 31 Mar, 2025 | BSE India | Pursuant to Reg 30 of SEBI (LODR) Reg 2015, Mr. SR Buddharaju - Independent Director has ceased to be an Independent Director of the Company upon completion of his tenure of two terms of 5 consecutive years w.e.f end of the day on March 31, 2025 |
| 26 Mar, 2025 | NSE India | MARKSANS PHARMA LIMITED has informed the Exchange about Closure of Trading Window |
| 26 Mar, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
| 21 Mar, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange about Schedule of meet |
| 21 Mar, 2025 | BSE India | This is to inform that official of the Company will participate in the investor/analyst conference i.e. Motilal Oswal India Ideation conference on 25 March 2025 at 10:00 am at Grand Hyatt, Mumbai. |
| 20 Mar, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange regarding a press release dated March 20, 2025, titled ""Marksans Pharma Limited s manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, has been approved by Australian TGA for manufacture of pharmaceutical formulations for Australian markets."". |
| 20 Mar, 2025 | BSE India | Kindly find enclosed press release dated 20th March 2025 |
| 19 Mar, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange regarding a press release dated March 19, 2025, titled ""Marksans Pharma Limited s wholly owned subsidiary in the UK, Relonchem Limited receives Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA"". |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 23 Jan, 2025 | 11 Feb, 2025 |
| Quarterly Results | -- | 24 Oct, 2024 | 12 Nov, 2024 |
| Quarterly Results | -- | 01 Aug, 2024 | 13 Aug, 2024 |
| Audited Results & Final Dividend | -- | 14 May, 2024 | 30 May, 2024 |
| Quarterly Results | -- | 18 Jan, 2024 | 13 Feb, 2024 |
| Quarterly Results | -- | 30 Oct, 2023 | 09 Nov, 2023 |
| Quarterly Results | -- | 03 Aug, 2023 | 11 Aug, 2023 |
| Audited Results & Final Dividend | -- | 18 May, 2023 | 30 May, 2023 |
| Quarterly Results | -- | 06 Feb, 2023 | 13 Feb, 2023 |
| Others | Inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis. | 12 Jan, 2023 | 20 Jan, 2023 |
Share Holding Pattern
| Owner Name | Sept, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
|---|---|---|---|---|---|
| Promoter Group | 43.87% | 43.85% | 49% | 48.25% | 48.25% |
| Foreign Institutions + | 21.31% | 15.55% | 4.23% | 2.59% | 3.79% |
| Domestic Institutions + | 4.1% | 4.76% | 0.96% | 0.41% | 1.56% |
| Government | 0% | 0% | 0% | 0% | 0% |
| Public | 30.72% | 35.84% | 45.81% | 48.75% | 46.4% |
| Others | 0% | 0% | 0% | 0% | 0% |
About Marksans Pharma
Marksans Pharma is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.27 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1992
Managing Director
Mr. Mark Saldanha
NSE Symbol
MARKSANS
Marksans Pharma Management
| Name | Designation |
|---|---|
| Mr. Mark Saldanha | Chairman & Managing Director |
| Mrs. Sandra Saldanha | Whole Time Director |
| Mr. Varddhman V Jain | Whole Time Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Seetharama R Buddharaju | Independent Director |
| Mr. Digant Mahesh Parikh | Independent Director |
| Mr. Abhinna Sundar Mohanty | Independent Director |
| Mrs. Shailaja Vardhan | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| Sun Pharmaceutical Industries | ₹4,10,130.32 | ₹1,709.35  ₹1,770.00(-3.43%) | ₹1,376.750 - ₹1,960.200 |
| Divi's Laboratories | ₹1,45,552.44 | ₹5,482.85 ₹5,763.00(-4.86%) | ₹3,613.550 - ₹6,448.750 |
| Cipla | ₹1,14,298.01 | ₹1,415.25 ₹1,495.70(-5.38%) | ₹1,317.600 - ₹1,702.000 |
| Torrent Pharmaceuticals | ₹1,11,230.09 | ₹3,286.50  ₹3,247.70(1.19%) | ₹2,508.650 - ₹3,589.950 |
| Mankind Pharma | ₹1,01,131.25 | ₹2,451.20 ₹2,427.70(0.97%) | ₹1,910.100 - ₹3,050.000 |
FAQs on Marksans Pharma
What is the share price of Marksans Pharma?
The share price of Marksans Pharma on 04 Apr, 2025 is ₹ 206.69.
What is 52W high and 52W low share price of Marksans Pharma?
The highest and lowest 52W share prices of Marksans Pharma are ₹ 358.500 and ₹ 130.150
What is the market cap of Marksans Pharma?
The market capitalization of Marksans Pharma as of 04 Apr, 2025 is ₹ 9,366.44 Crores
What is the P/E ratio of Marksans Pharma?
The current P/E ratio of Marksans Pharma as of 04 Apr, 2025 is 44.73
What is the PB ratio of Marksans Pharma?
The PB ratio of Marksans Pharma as of 04 Apr, 2025 is 4.49
Top Gainers
₹18.07
₹15.14 (0.19%)
₹66.60
₹57.80 (0.15%)
₹88.74
₹73.95 (0.20%)
₹197.50
₹167.35 (0.18%)
Top Losers
₹307.35
₹368.55 (-0.17%)
₹108.20
₹127.00 (-0.15%)
₹0.54
₹1.03 (-0.48%)
₹2,705.55
₹3,206.90 (-0.16%)
Market Indices
Sensex
₹75,364.69
₹76,295.36 (-0.01%)